Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo

Journal of Clinical Investigation

Volumn 112, Issue 4, 2003, Pages 575-587

  Adkins, Heather B ^a   Bianco, Caterina ^b   Schiffer, Susan G ^a   Rayhorn, Paul ^a   Zafari, Mohammad ^a   Cheung, Anne E ^a   Orozco, Olivia ^a   Olson, Dian ^a   De Luca, Antonella ^c   Chen, Ling Ling ^a   Miatkowski, Konrad ^a   Benjamin, Chris ^a   Normanno, Nicola ^c   Williams, Kevin P ^a,d   Jarpe, Matthew ^a   LePage, Doreen ^a   Salomon, David ^b   Sanicola, Michele ^a  

^a BIOGEN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Amphora Discovery Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A8.G3.5 ANTIBODY; ANTIBODY; CELL PROTEIN; CELL SURFACE ASSOCIATED PROTEIN; MYELOPID; PROTEIN; PROTEIN ALK4; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN; ACVR1B PROTEIN, HUMAN; ACVR1B PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR; EPITOPE; IMMUNOGLOBULIN G; LIGAND; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN NODAL; TDGF1 PROTEIN, HUMAN; TDGF1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TESTIS CANCER; TUMOR GROWTH; XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CELL SEPARATION; CELL TRANSFORMATION; CHEMISTRY; CHO CELL; DOSE RESPONSE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HAMSTER; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PLASMID; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; TIME;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PLASMIDS; PRECIPITIN TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 85047693731     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17788     Document Type: Article

References (49)

1. Gibbs, J.B. 2000. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Invest. 105:9-13.
2. de Bono, J.S., and Rowinsky, E.K. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8(Suppl. 4):S19-S26.
3. George, D. 2001. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 28:27-33.
4. Adamson, E.D., Minchiotti, G., and Salomon, D.S. 2002. Cripto: a tumor growth factor and more. J. Cell. Physiol. 190:267-278.
5. Ciardiello, F., et al. 1994. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene. 9:291-298.
6. Brennan, J., et al. 2001. Nodal signalling in the epiblast patterns the early mouse embryo. Nature. 411:965-969.
7. Ding, J., et al. 1998. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature. 395:702-707.
8. Gritsman, K., et al. 1999. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell. 97:121-132.
9. Shen, M.M., and Schier, A.F. 2000. The EGF-CFC gene family in vertebrate development. Trends Genet. 16:303-309.
10. Yan, Y.T., et al. 1999. Conserved requirement for EGF-CFC genes in vertebrate left-right axis formation. Genes Dev. 13:2527-2537.
11. Bianco, C., et al. 2002. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells. Mol. Cell. Biol. 22:2586-2597.
12. Yeo, C., and Whitman, M. 2001. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol. Cell. 7:949-957.
13. Kumar, A., et al. 2001. Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads. J. Biol. Chem. 276:656-661.
14. Bianco, C., et al. 2002. Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. J. Cell. Physiol. 190:74-82.
15. Schiffer, S.G., et al. 2001. Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J. Biol. Chem. 276:37769-37778.
16. Barcellos-Hoff, M.H., and Ewan, K.B. 2000. Transforming growth factor-beta and breast cancer: mammary gland development. Breast Cancer Res. 2:92-99.
17. Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117-129.
18. Risbridger, G.P., Schmitt, J.F., and Robertson, D.M. 2001. Activins and inhibins in endocrine and other tumors. Endocr. Rev. 22:836-858.
19. Wakefield, L.M., and Roberts, A.B. 2002. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12:22-29.
20. Muraoka, R.S., et al. 2002. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109:1551-1559. doi:10.1172/JCI200215234.
21. Yang, Y.A., et al. 2002. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109:1607-1615. doi:10.1172/JCI200215333.
22. van Schaik, R.H., et al. 2000. Variations in activin receptor, inhibin/ activin subunit and follistatin mRNAs in human prostate tumour tissues. Br. J. Cancer. 82:112-117.
23. Su, G.H., et al. 2001. ACVK1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. U. S. A. 98:3254-3257.
24. Kalkhoven, E., et al. 1995. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 6:1151-1161.
25. Adkins, H.B., Blacklow, S.C., and Young, J.A. 2001. Two Functionally distinct forms of a retroviral receptor explain the nonreciprocal receptor interference among subgroups B, D, and E avian leukosis viruses. J. Virol. 75:3520-3526.
26. Johnsson, B., Lofas, S., and Lindquist, G. 1991. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:268-277.
27. Alexander, J.M., Bikkal, H.A., Zervas, N.T., Laws, E.R., Jr., and Klibanski, A. 1996. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas. J. Clin. Endocrinol. Metab. 81:783-790.
28. Normanno, N., et al. 1995. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 35:293-297.
29. Normanno, N., et al. 2003. CRIPTO-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J. Cell. Physiol. In press.
30. Albano, R.M., Groome, N., and Smith, J.C. 1993. Activins are expressed in preimplantation mouse embryos and in ES and EC cells and are regulated on their differentiation. Development. 117:711-723.
31. Yan, Y.T., et al. 2002. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol. Cell. Biol. 22:4439-4449.
32. Qi, C.F., et al. 1994. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br. J. Cancer. 69:903-910.
33. Saeki, T., et al. 1995. Association of epidermal growth factor-related peptides and type 1 receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn. J. Clin. Oncol. 25:240-249.
34. Chen, Y.G., Lui, H.M., Lin, S.L., Lee, J.M., and Ying, S.Y. 2002. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood). 227:75-87.
35. Cocolakis, E., Lemay, S., Ali, S., and Lebrun, J.J. 2001. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J. Biol. Chem. 276:18430-18436.
36. Liu, Q.Y., et al. 1996. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res. 56:1155-1163.
37. Hahn, W.C., et al. 1999. Creation of human tumour cells with defined genetic elements. Nature. 400:464-468.
38. Kannan, S., et al. 1997. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J. Biol. Chem. 272:3330-3335.
39. Gray, P.C., et al. 2003. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc. Natl. Acad. Sci. U. S. A. 100:5193-5198.
40. Chong, H., et al. 2000. Structure and expression of a membrane component of the inhibin receptor system. Endocrinology. 141:2600-2607.
41. Massague, J., and Chen, Y.G. 2000. Controlling TGF-beta signaling. Genes Dev. 14:627-644.
42. Jing, S., et al. 1996. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 85:1113-1124.
43. Sanicola, M., et al. 1997. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc. Natl. Acad. Sci. USA. 94:6238-6243.
44. Treanor, J.J., et al. 1996. Characterization of a multicomponent receptor for GDNF. Nature. 382:80-83.
45. Cheng, S.K., Olale, F., Bennett, J.T., Brivanlou, A.H., and Schier, A.F. 2003. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 17:31-36.
46. Bruckner, K., Perez, L., Clausen, H., and Cohen, S. 2000. Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature. 406:411-415.
47. Hicks, C., et al. 2000. Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Norch2. Nat. Cell Biol. 2:515-520.
48. Moloney, D.J., et al. 2000. Fringe is a glycosyltransferase that modifies Norch. Nature. 406:369-375.
49. Moloney, D.J., et al. 2000. Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules. J. Biol. Chem. 275:9604-9611.